Thymosin Alpha-1 Manufacturing, Supply & Shortage History
At a glance
- Approval status / Not FDA-approved; no US application found [1]
- Finished product / Zadaxin 1.6 mg vials, sold outside the US [1]
- Named authorizations / Italy, India, Hong Kong [1]
- Pharmacy compounding list / In none of the three categories [2]
- Outsourcing-facility list / Category 3, 'nominated without adequate support' [3]
- Safety-risk list / 'Nominated but withdrawn' table [8]
- Advisory committee vote / 4 yes, 17 no, December 2024 [4]
Is thymosin alpha-1 FDA-approved?
No. A Drugs@FDA search in FDA's December 2024 review found no application for thymosin alpha-1 or thymalfasin [1]. It holds four US orphan drug designations, but orphan designation is a separate process and is not an approval [1].
Where the finished product is sold
Thymosin alpha-1 is a 28-amino-acid peptide with an acetylated N-terminal end, originally isolated from thymosin fraction 5, a thymus extract; thymalfasin is the synthetic version with the same sequence. Zadaxin is the brand of the finished injection sold outside the US at 1.6 mg per vial, and it is not interchangeable with bulk thymosin alpha-1 powder [1].
FDA names three national authorizations: Italy, as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 and older with compensated liver disease and virus replication; and Hong Kong [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, not a marketing approval [1]. Two reviews by authors tied to the Zadaxin developer put the reach at 'over 35 countries' in 2009 [5] and 'more than 30' in 2007 [6].
Can US compounders supply it from bulk peptide?
Under FDA's rules for state-licensed pharmacies, a bulk substance must comply with a USP or NF monograph, be a component of an FDA-approved drug, or appear on FDA's bulks list [7]. Thymosin alpha-1 is in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026). On the outsourcing-facility list (updated March 21, 2025) it is in category 3, 'nominated without adequate support', and FDA's category 1 no-action policy does not apply to it [2][3].
Thymosin alpha-1 had been in category 2 (significant safety risks) and now sits in FDA's 'nominated but withdrawn' table because the nominators withdrew. FDA's posted concerns remain: a significant risk of immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information inadequate to understand the extent of any safety issues [8]. On December 4, 2024 the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate [4]. HHS's October 2026 draft enforcement-discretion policy names six other peptides and not this one [9].
Questions worth asking
Frequently asked questions
Is thymosin alpha-1 FDA-approved?
Can US pharmacies compound thymosin alpha-1?
Is Zadaxin the same as bulk thymosin alpha-1 powder?
Does the HHS peptide policy cover thymosin alpha-1?
References
Show all 9 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608.
- Tuthill C. Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing. Ann N Y Acad Sci. 2007;1112:351-6.
- Bulk Drug Substances Used in Compounding | FDA.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Official web page.